Press Coverage

Hepatitis C Treatment: Study Finds No Liver, Kidney or Cardiovascular Adverse Effects

June 10, 2019

Interview mentions that an ISMP QuarterWatch^TM report raising questions about whether direct acting antiviral medications for the treatment of Hepatitis C posed any significant safety risks for patients was the impetus for further study.

For the full text, visit MedicalResearch.com online.

More News

News Release 05/18/2021

ISMP Launches Perioperative Medication Safety Self Assessment

New Tool Will Help Surgery Sites Evaluate, Document Compliance, Compare Scores

Press Coverage 05/06/2021

Drug Diversion in Healthcare

This article appeared in American Nurse Journal website on May 6, 2021.

News Release 04/23/2021

ISMP Analyzes First Few Months of COVID-19 Vaccine Errors

Since COVID-19 vaccines were granted emergency use authorization, The Institute for Safe Medication Practices (ISMP) has received reports of errors related to storage, preparation, and administration. Because COVID-19 vaccine errors can result in reduced effectiveness, and other safety implications